Interleukin-2 and histamine in combination inhibit tumour growth and angiogenesis in malignant glioma by Johansson, M et al.
Patients with malignant astrocytoma, the most common primary
brain tumour, have a poor prognosis. Radical surgery is usually not
possible due to the infiltrative growth of the tumour, and if
combined with radiotherapy a median survival time of 10–12
months can be achieved. Despite many efforts using a pharma-
cotherapeutic approach, no major advantages have so far been
seen. Some interesting, though controversial, results have been
obtained with immunotherapy including interleukin-2 (IL-2) in
various experimental systems, as well as in the clinical setting, for
malignant glioma (Takai et al, 1988; Barba et al, 1989a; Weber et
al, 1989; Lillehei et al, 1991; Fleshner et al, 1992; Saris et al, 1992;
Danaila et al, 1993; Hayes et al, 1995; Glick et al, 1997; Kruse et
al, 1997; Fathallah Shaykh et al, 1998).
The central role of the cytokine IL-2 in activating NK cells and
tumour infiltrating lymphocytes (Caligiuri et al, 1993) has encour-
aged trials of IL-2 in patients with solid cancers such as malignant
melanoma and renal cell carcinoma. The impact on overall
survival has, however, been questioned (Ljungberg and
Henriksson, 1997; Henriksson et al, 1998). The detailed mecha-
nisms, which explain the poor outcome, have not been fully
delineated. Patients with cancer are presumed to respond less to
immune stimuli than healthy controls and several hypotheses have
been proposed to explain the poor immunogenicity of tumours.
Recent in vitro studies suggest that NK cells are only weakly acti-
vated by IL-2 in the presence of phagocytes, presumably due to the
production of an inhibitory signal from phagocytes (Hellstrand et
al, 1994a; 1994b). It has been shown that histamine abrogates the
phagocyte-derived suppressive signal and thus facilitates the IL-2-
induced NK cell-mediated killing of tumour cells (Hellstrand and
Hermodsson, 1990; Hellstrand et al, 1994a; Asea et al, 1996).
Interestingly, NK cell targets seem to be of special importance in
cytotoxic immune response in rat glioma (Holladay et al, 1992).
Moreover, it has also been demonstrated that histamine enhances
the anti-tumour effects of IL-2 and irradiation in a rat prostatic
carcinoma (Johansson et al, 1998).
In consideration of the above we found it of interest to investi-
gate whether treatment with histamine in combination with IL-2
affects the growth of intracerebral malignant glioma in rats. In
addition, since it is known that histamine and IL-2 both affect the
vascular function by increasing permeability (Alexander et al,
1989; Nomura et al, 1994) we evaluated the possible effects on
tumour microvessel function and morphology.
MATERIALS AND METHODS
Tumour model and animal care
The previously described intracerebral syngenic BT4C rat glioma
model was used for the experiments (Bergenheim et al, 1994;
Johansson et al, 1997). Briefly, BT4C rat glioma cells were
suspended to a concentration of 20 000 cells per 5 µ l in minimal
essential medium (MEM, Flow laboratories, Scotland). Inbred
BDIX rats were anaesthetized with a 1:1 mixture of Hypnorm®
(fluanisonum 10 mg ml–1 and fentanylum 0.2 mg ml–1) and
Dormicum® (midazolam 5 mg ml–1) 1.8 ml–1 kg–1 administered as
a single i.p. injection. With the aid of a 22G microsyringe
(Unimetrics, Shorewood, Illinois, USA) fitted to the micro-
manipulator of a stereotactic frame 2 × 104 cells were transplanted
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doi: 10.1054/ bjoc.2000.1354, available online at http://www.idealibrary.com on stereotactically to the right caudate nucleus of the rat brain. The
animals were housed in a controlled environment (12 h light/12 h
dark) with pellets and water freely available. The experiments
were approved by the local ethics committee with the recommen-
dation of using a limited number of animals. Eight rats were
chosen at random for IL-2 treatment, 10 rats for histamine treat-
ment, eight rats for treatment with a combination of IL-2 and hist-
amine and 20 rats served as untreated controls.
IL-2 and histamine administration
IL-2 was continuously delivered by a subcutaneous infusion using
Alzet 2002 micro-osmotic pumps (Alza Corporation, Palo Alto, CA,
USA). The pumps containing 200 µ L IL-2 at a concentration of 
1 800 000 IU ml–1 were implanted subcutaneously on day 6 after
tumour implantation, when small solid tumours are known to have
been formed (Bergenheim et al, 1994). The micro-osmotic pump
system makes it possible to deliver 0.5 µ l h–1 for 14 days (Henriksson
et al, 1992). The daily dose delivered in this way was 21 600 IU 
24 h–1, or approximately 66 000 IU kg–1 24 h–1. The IL-2 infusion was
continued until day 20 after tumour implantation. Histamine was
administrated as daily subcutaneous injections at a dose of 4 mg kg–1.
Histamine treatment started the day after implantation of IL-2 pumps
and continued until the termination of the experiment.
Tumour growth
The study was terminated on day 24 after tumour implantation,
when animals were decapitated. The brains were immediately
carefully dissected and fixed in formaline. Tumours were measured
using a microcalliper. Tumour volume was calculated using the
formula for the ellipsoid (r1 × r2 × r3 × 4/3) where the radius in the
sagittal plane was approximated to be the same as the coronal
radius. Brains were thereafter fixed cold in 70% ethanol until
paraffin embedded. For routine histological staining and immuno-
histochemistry 4 µ m sections were cut using a sledge microtome.
For immunohistochemistry, tissue sections were mounted on
polylysin coated slides.
Vascular staining and assessment of microvascular
density
Vessels in the BT4C brain tumours were immunohistochemically
stained for factor VIII and quantified manually using a method
originally presented by Weidner and coworkers (Weidner, 1993).
Sections chosen for immunohistochemical staining were
deparaffinized, rehydrated and permeabilized in 0.05% protease
P27 at 37° C for 30 min. After blocking with normal goat sera
sections were incubated for 1 h at room temperature with a poly-
clonal rabbit anti-human factor VIII antibody (DAKO A/S,
Denmark) diluted 1:200. After washing in PBS, sections were
incubated with biotinylated goat anti-rabbit antibody and avidin
linked alkaline phosphatase (Vector ABC-AP, Vector, Burlingame,
CA, USA). Sections were developed using alkaline phosphatase
reagent (Vector) and finally mounted using gelatin-glycerol.
Assessment of microvascular density (MVD) was performed by
manual counting in selected areas with high vascular density (hot-
spots). Each tumour was scanned at low magnification and four
hot-spots were chosen for MVD quantification. All stained objects
within a 200× field (1.23 mm2) were counted using a standard light
microscope (Axiophot, Zeiss, Germany). Each hot-spot was
counted twice and the arithmetical mean in each spot was used to
calculate the mean MVD for each tumour section, which was used
for further statistical analysis. MVD was expressed as number of
vessels mm–2.
In order to get quantitative information on tumour vessel size,
the sections were also analysed using a computerized image
analysis system (CIAS). The system used consists of a standard
microscope (Axiophot, Zeiss, Oberkochen, Germany) fitted with a
high resolution digital camera (ProgRes 3000, Kontron Elektronik
GmbH, Eching bei München, Germany) under control of WinCam
1.4 software (CCD-Videometrie, Unterscheissheim, Germany) in a
PC computer. Images were thereafter analysed using KS-400 2.00
software (Kontron Elektronik). The image analysis procedure was
automatized by a KS-400 macro with individual threshold setting
for each section. Threshold setting was subjectively verified by
superimposing the contours of the obtained binary image on the
original. If detectable mismatch was found, the procedure of
thresholding was redone until congruence was achieved. Four
vascular hot-spots was data from each spot at 200× magnification
(area 0.307 mm2). For each vessel in each area the perimeter, area,
maximal diameter and minimal diameter was measured and stored
in a database. Means for each tumour were calculated and used for
further statistical analysis. Frequency distributions of the vessel
areas were based on the entire database divided into the different
groups of treatment.
VEGF expression
The mRNA expression of VEGF was evaluated by in situ hybridiza-
tion in histological sections from at least four different tumours in
each treatment group. In situ hybridization for vascular endothelial
growth factor (VEGF) was performed mainly as previously
described (Lindgren et al, 1997), modified for formalin fixed
paraffin embedded sections. Briefly, specific polymerase chain reac-
tion (PCR) primers were selected for rat glioma derived VEGF and
reverse transcriptase (RT) PCR was performed on 1 µ g tumour
mRNA. Following cloning into a commercially available plasmid
(Bluescript SK +/–, Stratagene, La Jolla, CA, USA) a digoxin
(DIG)-labelled RNA probe was obtained by using a DIG-RNA kit
(Boehringer Mannheim, Stockholm, Sweden) according to the
manufacturer’s recommendations. Formalin fixed sections were
dewaxed in xylene and rehydrated through a graded ethanol series.
Thereafter, sections were fixated in 4% paraformaldehyde
(PFA)/phosphate buffered saline (PBS), incubated in 0.2 M HCl,
acetylated and treated with proteinase K 25 µ g ml–1 to further break
formalin-induced protein changes. In situ hybridization was
performed with DIG-labelled RNA probes at a concentration of 
50 ng 100 µ l–1 at 70° C overnight. The DIG-labelled probes were
thereafter tracked by incubating sections with anti-DIG fabs
(Boehringer Mannheim). Development was carried out at 30° C with
5-Bromo-4-Chloro-3-Inolyl-Phosphate (Boehringer Mannheim), 50
mg ml–1 4-Nitro Blue Tetra-zoliumchloride (Boehringer Mannheim)
for 12 h. Finally, sections were mounted in gelatine glycerol medium.
Apoptosis
In situ end labelling (ISEL) is a method for visualization of
apoptotic cells in terms of DNA strand-breaks. The protocol of
Wijsman and coworkers was used (Wijsman et al, 1993). Sections
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according to routine histology procedures. After deparaffinization
and rehydration, the sections were heated twice in SSC (sodium
chloride 17.5 g, sodium citrate 8.8 g l–1 water, pH 7.0; Merck
Darmstadt, Germany) at 80° C for 20 min and subsequently
washed thoroughly in distilled water. To enable enzymatic incor-
poration of nucleotides, the sections were digested in 0.5% pepsin
in hydrochloric acid (pH 2) for 15 min with gentle shaking in a
37° C water bath. The digestion was stopped by washing several
times in tap water and then washed in buffer for 5 min. After
drying, the sections were incubated for 1 h at 15° C with buffer
containing 0.01 mM dATP, dGTP, dCTP and 0.01 mM biotin
dUTP (Boehringer Mannheim) along with 4 U ml–1 DNA poly-
merase 1 (Sigma, USA). Endogenous peroxidase was blocked for
5 min in PBS with 0.1% hydrogen peroxide, and the sections were
then washed twice in PBS (0.1% hydrogen peroxide). The sections
were incubated with avidin dissolved in PBS with 1% BSA
(bovine serum albumin) and 0.5% Tween 20 (Boehringer
Mannheim) for 30 min at room temperature before developing
with diaminobenzidine. In negative controls, DNA polymerase
was excluded from the nucleotide polymerase mix. Normal rat
prostate, 3 days after castration, was used as a positive control.
The number of ISEL-positive cells was quantified in the light
microscope. Apoptotic index was expressed as the fraction apop-
totic cells of the total number of cells, expressed as percent.
Tumour infiltrating macrophages
Sections chosen for immunohistochemical staining of
macrophages were deparaffinized in xylene, rehydrated in graded
ethanol series and washed in deionized water. The tissue was
thereafter permeabilized by microwave heating in 0.01 M citrate
buffer pH 6.0 for 5 min × 4 followed by washing in PBS for 5 min
× 4. Endogenous peroxidase activity was inhibited by incubation
in 3% H2O2 methanol for 20 min. Slides were then incubated with
normal goat serum for 20 min prior to overnight incubation at 8° C
with mouse anti-rat ED-1 antibody (MCA 341, Serotec Ltd,
Oxford, UK) diluted 1:200. After washing in PBS 5 min × 4 slides
were incubated with a biotinylated goat anti-mouse antibody
(Vector Laboratories) for 30 min and washed in PBS 5 min × 4
again. Sections were subsequently incubated with avidin linked
peroxidase (Vector ABC) for 20 min according to the vendor’s
recommendations. Development was finally performed using 3,3′ -
diaminobenzidine (DAB) tablets (Sigma) according to the manu-
facturer’s recommendations. After 5 min wash in tap water, slides
were mounted in gelatine glycerol. Immunohistochemistry for
ED-1 was performed on all tumours and staining was semiquanti-
tatively assessed by two observers as missing (0), weak (1),
moderate (2) or pronounced (3).
Tumour blood flow
To analyse blood flow in tumour tissue and normal brain, a model
utilizing single-fibre laser Doppler flowmetry was set up.
Recordings of tumour as well as normal cortex perfusion were
done simultaneously with a dual-channel Laser Doppler flowmeter
(Periflux PF4000, Perimed, Järfälla, Sweden) prior to and after
administration of histamine. The laser Doppler signal was trans-
ferred on line to a personal computer equipped with the Perisoft
software package (Perimed).
The left femoral artery was catheterized and the catheter was
connected to a pressure transducer for online registration of
systemic blood pressure. Immediately thereafter, animals were
fixed in a stereotactic frame (Kopf 900, David Kopf, Tujunga, CA,
USA) and the skull bone was exposed with a sagittal incision. Care
was taken to obtain optimal haemostasis. A burr hole 3.5 mm to
the left of bregma was made contralateral to the tumour implanta-
tion burr hole in the right hemisphere bone to expose the normal
left hemisphere. The dura mater was incised carefully. Two single-
fibre laser Doppler probes (Probe 418, Perimed) fitted to the
micromanipulator arms of the stereotactic instrument were there-
after advanced to a depth of 2 mm in the tumour and contralateral
brain hemisphere, respectively.
When adequate signal from the laser Doppler flowmeter was
obtained, the preparation was left undisturbed for 10 min to allow
the system to equilibrate. A baseline flow recording of at least 
5 min was performed prior to administration of histamine 4 mg
kg–1 s.c. Observation of changes in blood flow was continued for at
least 10 min after histamine administration. The maximal perfu-
sion change post-histamine administration was thereafter
compared to the mean baseline perfusion value using the Perisoft
software package (Perimed). Vascular resistance was calculated by
dividing mean arterial pressure with obtained flow values. Four
animals were randomly chosen for blood flow measurements 20
days after tumour implantation.
Statistical analysis
Values are expressed as means ± SE unless otherwise indicated.
For comparisons between groups Mann–Whitney U test was used.
For comparison of manual and computerized vascular counts,
linear regression was used. Statistical analysis was performed
using the StatView 4.5 software (Abacus Concepts, Berkely, CA,
USA) for the Macintosh (Apple Computer, Cupertino, CA, USA)
computer.
RESULTS
Tumour growth
The combination of IL-2 and histamine reduced tumour volume
(95 ± 11 mm3) significantly when compared to untreated controls
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Figure 1 Brain tumour volume (mm3) in control animals and animals treated
with histamine (Hist), IL-2 alone (IL-2) or histamine combined with IL-2 
(Hist + IL-2). Values are given as means ± SE. **P < 0.01 compared to control(169 ± 12 mm3) (P < 0.01). Histamine or IL-2 alone did not affect
tumour growth (156 ± 3m m 3 and 153 ± 14 mm3, respectively).
(Figure 1).
Morphology
Manifest tumours were identified in all animals (Figure 2A). ED-1
positive macrophages were identified in all examined tumours
(Figure 2B). ED-1-positive cells were mainly found infiltrating the
invasive border of the tumour where haemorrhages were common.
Histamine and/or IL-2 treated animals had a strong tendency of an
increase in ED-1-positive cells, especially in the tumour periphery
(Figure 2B, Figure 3) No central necrotic areas were found and
factor VIII-positive microvessels were found throughout the
tumour (Figure 2C). Vascular density was most intensive in the
periphery of tumours, where microvascular hot-spots most
commonly were identified. In situ hybridization of VEGF showed
no obvious changes following any of the treatments (Figure 2D).
The apoptotic index in the control group was 5.3 ± 3% and no
significant difference between the groups was observed. In the
positive control, i.e. rat prostate, a significant number of the
epithelial cells displayed characteristic features of apoptotic death
3 days after castration (not shown).
Microvascular density
Intratumoural microvascular density was significantly decreased
by the combination of IL-2 and histamine when compared to
untreated controls when counted manually (Table 1). Mean MVD
in the control group was 205 ± 13 vessels mm–2 compared to the
IL-2/histamine group where the average MVD was 152 ± 4.5
vessels mm–2 (P < 0.01). Neither histamine nor IL-2 did affect
tumour MVD significantly when given alone and the groups had a
mean MVD of 165 ± 16 vessels mm–2 and 174 ± 10 vessels mm–2
respectively.
MVD assessed by CIAS showed good correlation to the manu-
ally obtained data (r = 0.67) and the combination of IL-2 and hist-
amine was found to decrease MVD also when analysed with the
IL-2 and histamine in combination inhibit glioma growth 829
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Figure 2 Photomicrographs showing (A) haematoxylin-eosin stain of a control tumour (× 25), (B) ED-1 macrophage immunohistochemical stain (× 25), 
(C) factor VIII immunohistochemistry of a vascular hot-spot in a control animal (× 200) and (D) VEGF in situ hybridization demonstrating the high expression 
in tumour border (arrow) in a control animal (× 25). T indicates tumour and B normal brain tissue
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Figure 3 Semi-quantitative assessment of macrophages detected by ED-1
immunostaining in the centre and periphery of tumours. Staining classified 
as missing (0), low (1), moderate (2) or high (3). Values are given as 
means ± SECIAS. Noteworthy, individual tumour vessel size decreased signi-
ficantly when histamine was administered. Mean vessel area,
perimeter and diameter all decreased significantly in the histamine
group. The combination of IL-2 and histamine was found to
increase all vessel size parameters concomitantly with the
decrease in MVD (Table 1).
Tumour blood flow
Histamine administration rapidly decreased mean arterial pressure
from 89 ± 6 to 58 ± 4 mmHg followed by a significant decrease in
tumour perfusion (Figure 4). The tumour vascular resistance was
not altered following histamine administration while cerebral
vascular resistance decreased. Vascular resistance following hist-
amine injection expressed as percent of baseline was 97 ± 6% in
tumour and 65 ± 2% in the brain. Systemic blood pressure and
tumour perfusion returned to pre-histamine values after approxi-
mately 15 min. No change in normal brain perfusion was seen
during the experiment.
DISCUSSION
This study demonstrated for the first time, as far as we know, that
histamine in combination with IL-2 reduced the growth of an
intracerebral malignant glioma. The results are in accordance with
earlier observations that manipulation of the immune system with
histamine and IL-2 inhibits growth of extracranial experimental
tumours (Johansson et al, 1998). In addition to earlier suggested
immunological effects (Hellstrand and Hermodsson, 1990;
Hellstrand et al, 1994a), the present results propose that interaction
with tumour angiogenesis and tumour perfusion may be mecha-
nisms involved in the action of the combination of IL-2 and hista-
mine. Noteworthy, treatment with either IL-2 or histamine alone
was without any detectable effects on tumour growth.
Despite extensive efforts, a huge number of various pharmaco-
therapeutical approaches have shown a lack of meaningful clinical
benefits in malignant glioma. Immunotherapy has given some
interesting but so far clinically questionable results (Danaila et al,
1993; Hayes et al, 1995; Kruse et al, 1997). IL-2 alone, or used for
adoptive immunotherapy in conjunction with lymphokine-
activated killer (LAK) or tissue infiltrating lymphocytes (TIL),
showed some interesting experimental results (Tzeng et al, 1990;
Saris et al, 1992) but have demonstrated controversial results in
the clinical setting (Barba et al, 1989b; Lillehei et al, 1991). The
disappointing effects of immunotherapy in the management of
malignant glioma may be related to the feature of the intracerebral
compartment as immunologically privileged. Poor target recogni-
tion, limited major histocompatibility antigen expression, incom-
plete trafficking of immuno-effector cells across the blood–brain
barrier and redeeming actions of tumour cells that hamper
cytolytic activity of effector cells, might all contribute to difficul-
ties in brain tumour immunotherapy (Fontana et al, 1984; Tzeng et
al, 1990; Saris et al, 1992). The previously discussed immunologic
mechanisms of action of histamine (Hellstrand et al, 1990; 1994a)
could thus be of interest to explain the present obtained results.
In this study, treatment with histamine and IL-2 in combination
also significantly reduced the density of tumour microvessels.
Both IL-2 and histamine are known to affect tumour vasculature
by increasing permeability (Alexander et al, 1989; Nomura et al,
1994) but the finding that histamine and IL-2 in combination
decreases tumour MVD is novel, according to our knowledge.
Recent investigations have also suggested that the tumour vascula-
ture may be an important target for activated NK cells, and VEGF
has been shown to increase adhesion of NK cells to tumour
endothelium (Melder et al, 1996). Therefore, it may be proposed
that inhibition of tumour angiogenesis or damage to manifest
tumour vessels may be an additional mechanism of action for hist-
amine in combination with IL-2. Individual tumour vessel size was
found to increase concomitantly with the observed decrease in
tumour MVD after combination treatment with histamine and IL-
2. This may reflect the fact that fewer microvessels are generated
in the combination-treated tumours and one may speculate that the
combination of histamine and IL-2 is angiostatic rather than
angiotoxic. The lack of patchy haemorrhagic necrosis in treated
tumours supports this speculation. Anyhow, the molecular mecha-
nisms behind the decrease in MVD remain unclear and further
studies are needed. In this study we were not able to show any
obvious change in the pattern of VEGF expression or apoptotic
cell death. Thus, it might indicate that this treatment does not
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Table 1 Computerized image analysis of microvascular density (MVD), perimeter, area, minimum diameter and
maximum diameter in treated and not treated intracerebral rat glioma
Group IA MVD Perimeter Area D Min D Max
(v mm–2)( µ m) (µ m2)( µ m) (µ m)
Controls 200 ± 18 108 ± 7.0 217 ± 24 13 ± 0.7 26 ± 1.4
Histamine 175 ± 14 78 ± 5.9* 110 ± 13* 9.8 ± 0.5* 20 ± 1.1**
IL-2 154 ± 5.5 98 ± 4.3 180 ± 16 12 ± 0.5 25 ± 1.0
Hist + IL-2 128 ± 5.7** 135 ± 4.6* 336 ± 18** 15 ± 0.5* 32 ± 1.0**
Values are given as means ± SE. *P < 0.05, **P < 0.01 compared to control
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Figure 4 Tumour blood flow (TBF) and cerebral blood flow (CBF) after
administration of saline (control) and histamine as assessed by single-fibre
laser Doppler flowmetry (LDF). Values are given as mean percent of baseline
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interfere with VEGF-mediated angiogenesis. However, VEGF is
shown to increase endothelial cell surface expression of adhesion
molecules and thus may facilitate NK cells to bind and kill
endothelial cells (Melder et al, 1996). In our tumour model VEGF
expression is increased at the tumour border and this may be a
prerequisite for IL-2-activated NK cells to attach to tumour
endothelium (Lindgren et al, 1997).
The failure of IL-2 alone to induce a detectable tumour response
in our study finds support in recent published studies (Fathallah
Shaykh et al, 1998) and further emphasizes the complexity of
immunotherapy in malignant glioma. An IL-2 dose of the same
magnitude as used in this study has previously been seen to cause
significant anti-tumour effects in extracranially located rat
prostatic carcinoma and thus most probably demonstrates that 
an effective systemic concentration of IL-2 was achieved
(Henriksson et al, 1992; Johansson et al, 1998). However, even if
the dose of IL-2 was relatively high, one explanation of the lack of
effect of IL-2 in our orthotopic glioma model could be that the
concentration of IL-2 in the intracerebral compartment was not
optimal. Previously, it has been shown that histamine has the
ability to increase vascular permeability in an experimental intra-
cerebral glioma, but not in normal brain vessels (Nomura et al,
1994). The addition of histamine could thus increase the possi-
bility to achieve a sufficient concentration of IL-2 in the brain
tumour and also to enhance the permeability of blood–brain-
tumour barrier for immunocompetent cells. Subsequently, an
effective immunological reaction could be achieved in the
intracranial tumour compartment. In accordance with these
assumptions it could be noticed that intratumoural injection of IL-
2 in human glioma grade IV in nude mice caused growth retarda-
tion (Weber et al, 1989).
All examined tumours in this study were positive for the
specific marker for a cell-surface antigen on macrophages –
phagocytes, ED-1 (Dijkstra et al, 1985). The ED-1 positive cells
were mainly found in the invasive border of the tumour where the
microvascular density and VEGF expression is known to be high
(Lindgren et al, 1997). It is therefore tempting to speculate that
histamine reduces the inhibitory effects of phagocytes on IL-2-
stimulated NK cells, which may have the ability to block NK cells
infiltrating the tumour, as previously discussed (Hellstrand et al,
1990; 1994a). In this respect it is of interest to recall the observa-
tion that cytotoxic lymphocyte responses in rat glioma have
consistently been shown against NK cell targets (Holladay et al,
1992). Since tumour-associated macrophages are known to either
stimulate angiogenesis (via tumour necrosis factor α ) or inhibit
angiogenesis (via GM-CSF and plasminogen activator inhibitor-2)
it can be speculated that histamine might promote the anti-
angiogenic effects (Joseph and Isaacs, 1998) as seen in this study.
The release of secondary cytokines following IL-2 may further
contribute to the observed complex effects seen. It is also of
interest that the high VEGF expression observed in the invasive
tumour border correlates with the presence of ED-1 positive
phagocytes. The presence of phagocytes in the tumour region
where NK cell-mediated endothelial cell killing is supposed to be
highest may explain the lack of effect on tumour vasculature of IL-
2 alone.
Histamine also induces a rapid and temporary decline in tumour
blood flow (TBF) without affecting normal brain perfusion. The
decrease in TBF is clearly an effect of reduced perfusion pressure
due to transient systemic hypotension. Tumour vascular resistance
remains unchanged while resistance in normal brain tissue
decreases after histamine administration. This finding illustrates
the lack of autoregulation in tumour tissue and the possibility to
modulate tumour blood flow with alterations in systemic blood
pressure. A reduction of tumour blood flow of the magnitude seen
in this experiment could possibly induce vascular shut down and
hypoxia, which might explain the haemorrhagic necrosis observed
by other authors following histamine treatment (Burtin et al, 1982;
Johansson et al, 1998). However, in this study we did not observe
any morphological changes indicating acute vascular damage
inflicted by the treatment. The lack of haemorrhagic necrosis in
our study may be due to the relatively short duration of histamine
treatment allowed in the fast growing intracerebral tumour model,
compared to the more slowly growing subcutaneous tumour model
used (Johansson et al, 1998).
Histamine and IL-2 are both commercially available for human
use and the clinical usefulness of this treatment combination is to
be evaluated. However, in the clinical setting there are some
obvious concerns. First, corticosteroids are known to down-
regulate VEGF expression and the use of steroids may therefore
also decrease the NK cell-mediated endothelial cell killing (Bruce
et al, 1987; Heiss et al, 1996). Second, the decrease in tumour
blood flow seen after histamine administration should be consid-
ered if histamine is used in combination with other agents aimed at
tumour cells. Third, the potential risk of cerebral oedema and
increased intracranial pressure due to increased blood vessel
permeability, induced both by histamine and IL-2, must also be
considered in the clinical situation (Barba et al, 1989b).
In conclusion, these results suggest that the novel combination
of IL-2 and histamine could be of interest in improving the thera-
peutic outcome in malignant glioma. In addition to direct immuno-
logical mechanisms it is suggested that inhibition of tumour
angiogenesis may be a new mechanism of action for the combina-
tion of IL-2 and histamine. However, further studies are needed to
delineate the mechanisms of action and to find the optimal
schedule of this treatment before the value of this approach can be
established.
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